Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS
September 22, 2021 06:00 ET
|
Enlivex Therapeutics Ltd
Top-line data from the randomized, multi-center trial are expected in Q2-2022 Nes-Ziona, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a...
Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
August 15, 2021 06:00 ET
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Aug. 15, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today reported that...
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update
August 09, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Top-line results from Phase IIb sepsis trial expected in Q2 2022Phase IIb trial in severe and critical COVID-19 patients planned for initiation in Q3 2021Initiation of a Phase Ib trial...
Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant
August 02, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Mr. Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer, and previously served as Chief Operating Officer of Protalix Biotherapeutics, and as General Manager of ColBar...
Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021
July 21, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, July 21, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex to Present at the ARDS Drug Development Summit 2021
July 14, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, July 14, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant
July 12, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, July 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it...
Enlivex Annouces Participation in A.G.P.’s Upcoming 2021 Virtual Summer Healthcare Symposium
June 16, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer
June 15, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...